Novogen Limited (NASDAQ:KZIA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Novogen Limited (NASDAQ:KZIA) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $26.3333.

Several research analysts have commented on the stock. Lake Street Capital assumed coverage on shares of Novogen in a research report on Thursday, June 11th. They issued a “buy” rating and a $32.00 target price for the company. BTIG Research reaffirmed a “buy” rating and set a $34.00 price target on shares of Novogen in a report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research report on Friday, July 17th. Finally, Canaccord Genuity Group initiated coverage on Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price objective for the company.

Novogen Stock Down 1.5%

KZIA stock opened at $13.20 on Tuesday. Novogen has a fifty-two week low of $4.86 and a fifty-two week high of $17.40. The firm’s 50-day simple moving average is $13.41 and its 200 day simple moving average is $11.00.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.